Chronic Obstructive Pulmonary Disease (COPD) is a severely disabling lung illness and is currently the fourth most common cause of death worldwide. Available therapeutics mostly target symptom relief, leaving a strong need for new, disease-targeted medications.?
Using a novel screening approach, researchers at Strathclyde have identified subtype selective Phosphodiesterase 4 (PDE4)? inhibitors. These are being optimised with the aim of delivering 'best in class' therapeutics to reduce the destructive lung inflammation that characterises COPD.
· Predicted superior efficacy and safety over current therapies.
· Potential to slow or halt disease progression.
· Improved tolerability compared to 'global' PDE4 inhibitors?.
Markets and Applications
COPD has a high average incidence rate of 8.1% in the general population of the seven major pharmaceutical markets, with the global COPD market projected to reach $14bn per year by 2014 and continue to expand through a combination of increasing incidence and improved screening and diagnosis.
Patent applications will be filed upon identification of strong lead candidates. Funding will then be sought for formation of a University of Strathclyde spin-out company to create additional value through identification and profiling of preclinical drug candidates for partnership or sale.